MYC and prostate cancer: Western blot analysis confirmed robust downregulation of direct targets (SMARCA2, SMARCA4, and PBRM1) and specific prostate cancer lineage proteins (AR, ERG, C-Myc, and PSA) after 5 d of AU-24118 treatment, whether administered alone or in combination with enzalutamide (Fig. 2E).